English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Mary-Jane Lombardo, PhD1, Marin Vulic, PhD1, Toshi Ohsumi, PhD1, David Cook, PhD1, Matthew Henn, PhD1, Colleen Kraft, MD2, Sahil Khanna, MBBS, MS3, Darrell Pardi, MD, MS3 and Elizabeth Hohmann, MD, FIDSA4 (1)Seres Therapeutics, Inc, Cambridge, MA, (2)Emory University School of Medicine, Atlanta, GA, (3)Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, (4)Infectious Diseases, Massachusetts General Hospital, Boston, MA Vancomycin-resistant enterococcal (VRE) titers diminish among patients with recurrent Clostridium difficile infection after administration of SER-109, a novel microbiome agent

open forum infectious diseases

Vancomycin-Resistant Enterococcal iters Diminish Among Patients With Recurrent Clostridium difficile Infection After Administration of SER-109, A Novel Microbiome Agent